{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:45:39Z","timestamp":1793047539360,"version":"4.5.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T00:00:00Z","timestamp":1707436800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T00:00:00Z","timestamp":1707436800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Kom op tegen Kanker (Stand up to Cancer), the Flemish cancer society","award":["7878"],"award-info":[{"award-number":["7878"]}]},{"name":"BOF grant of the University of Antwerp","award":["FFB210425"],"award-info":[{"award-number":["FFB210425"]}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["G040120N"],"award-info":[{"award-number":["G040120N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["1S76421N"],"award-info":[{"award-number":["1S76421N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["1S72821N"],"award-info":[{"award-number":["1S72821N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["1S27021N"],"award-info":[{"award-number":["1S27021N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["G053518N"],"award-info":[{"award-number":["G053518N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>It remains challenging to obtain positive outcomes with chimeric antigen receptor (CAR)-engineered cell therapies in solid malignancies, like colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC). A major obstacle is the lack of targetable surface antigens that are not shared by healthy tissues. CD70 emerges as interesting target, due to its stringent expression pattern in healthy tissue and its apparent role in tumor progression in a considerable amount of malignancies. Moreover, CD70 is also expressed on cancer-associated fibroblasts (CAFs), another roadblock for treatment efficacy in CRC and PDAC. We explored the therapeutic potential of CD70 as target for CAR natural killer (NK) cell therapy in CRC, PDAC, focusing on\u00a0tumor cells and CAFs, and lymphoma.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>RNA-seq data and immunohistochemical analysis of patient samples were used to explore CD70 expression in CRC and PDAC patients. In addition, CD70-targeting CAR NK cells were developed to assess cytotoxic activity against CD70<jats:sup>+<\/jats:sup> tumor cells and CAFs, and the effect of cytokine stimulation on their efficacy was evaluated. The in vitro functionality of CD70-CAR NK cells was investigated against a panel of tumor and CAF cell lines with varying CD70 expression. Lymphoma-bearing mice were used to validate in vivo potency of CD70-CAR NK cells. Lastly, to consider patient variability, CD70-CAR NK cells were tested on patient-derived organoids containing CAFs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In this study, we identified CD70 as a target for tumor cells and CAFs in CRC and PDAC patients. Functional evaluation of CD70-directed CAR NK cells indicated that IL-15 stimulation is essential to obtain effective elimination of CD70<jats:sup>+<\/jats:sup> tumor cells and CAFs, and to improve tumor burden and survival of mice bearing CD70<jats:sup>+<\/jats:sup> tumors. Mechanistically, IL-15 stimulation resulted in improved potency of CD70-CAR NK cells by upregulating CAR expression and increasing secretion of pro-inflammatory cytokines, in a mainly autocrine or intracellular manner.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>We disclose CD70 as an attractive target both in hematological and solid tumors. IL-15 armored CAR NK cells act as potent effectors to eliminate these CD70<jats:sup>+<\/jats:sup> cells. They can target both tumor cells and CAFs in patients with CRC and PDAC, and potentially other desmoplastic solid tumors.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13045-024-01525-w","type":"journal-article","created":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T01:41:55Z","timestamp":1707442915000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":106,"title":["IL-15-secreting CAR natural killer cells directed toward the pan-cancer target CD70 eliminate both cancer cells and cancer-associated fibroblasts"],"prefix":"10.1186","volume":"17","author":[{"given":"Astrid","family":"Van den Eynde","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Gehrcken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tias","family":"Verhezen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho Wa","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Hermans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilde","family":"Lambrechts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tal","family":"Flieswasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Quatannens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gils","family":"Roex","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Zwaenepoel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elly","family":"Marcq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Joye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar","family":"Cardenas De La Hoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Deben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Gasparini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Montay-Gruel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxim","family":"Le Compte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Lion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Lardon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Van Laere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliki","family":"Siozopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Campillo-Davo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorrit","family":"De Waele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Pauwels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelien","family":"Smits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas R. M.","family":"Van Audenaerde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,9]]},"reference":[{"issue":"10","key":"1525_CR1","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.3390\/cancers11101611","volume":"11","author":"T Flieswasser","year":"2019","unstructured":"Flieswasser T, Camara-Clayette V, Danu A, Bosq J, Ribrag V, Zabrocki P, et al. Screening a broad range of solid and haematological tumour types for CD70 expression using a uniform IHC methodology as potential patient stratification method. Cancers (Basel). 2019;11(10):1611.","journal-title":"Cancers (Basel)."},{"key":"1525_CR2","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s10142-023-00977-6","volume":"23","author":"F Kong","year":"2023","unstructured":"Kong F, Ye Q, Xiong Y. Comprehensive analysis of prognosis and immune function of CD70-CD27 signaling axis in pan-cancer. Funct Integr Genom. 2023;23:48.","journal-title":"Funct Integr Genom"},{"issue":"17","key":"1525_CR3","doi-asserted-by":"publisher","first-page":"7622","DOI":"10.7150\/thno.43991","volume":"10","author":"M Yang","year":"2020","unstructured":"Yang M, Tang X, Zhang Z, Gu L, Wei H, Zhao S, et al. Tandem CAR-T cells targeting CD70 and B7\u2013H3 exhibit potent preclinical activity against multiple solid tumors. Theranostics. 2020;10(17):7622\u201334.","journal-title":"Theranostics"},{"issue":"3","key":"1525_CR4","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.coi.2005.04.004","volume":"17","author":"J Borst","year":"2005","unstructured":"Borst J, Hendriks J, Xiao Y. CD27 and CD70 in T cell and B cell activation. Curr Opin Immunol. 2005;17(3):275\u201381.","journal-title":"Curr Opin Immunol"},{"key":"1525_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pharmthera.2015.07.007","volume":"155","author":"J Jacobs","year":"2015","unstructured":"Jacobs J, Deschoolmeester V, Zwaenepoel K, Rolfo C, Silence K, Rottey S, et al. CD70: an emerging target in cancer immunotherapy. Pharmacol Ther. 2015;155:1\u201310.","journal-title":"Pharmacol Ther"},{"issue":"1","key":"1525_CR6","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13046-021-02215-y","volume":"41","author":"T Flieswasser","year":"2022","unstructured":"Flieswasser T, Van den Eynde A, Van Audenaerde J, De Waele J, Lardon F, Riether C, et al. The CD70-CD27 axis in oncology: the new kids on the block. J Exp Clin Cancer Res. 2022;41(1):12.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"1525_CR7","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1038\/s41467-023-37614-6","volume":"14","author":"L Gong","year":"2023","unstructured":"Gong L, Luo J, Zhang Y, Yang Y, Li S, Fang X, et al. Nasopharyngeal carcinoma cells promote regulatory T cell development and suppressive activity via CD70-CD27 interaction. Nat Commun. 2023;14(1):1912.","journal-title":"Nat Commun"},{"issue":"3","key":"1525_CR8","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.pan.2021.01.013","volume":"21","author":"K Nakamura","year":"2021","unstructured":"Nakamura K, Sho M, Akahori T, Nishiwada S, Kunishige T, Nakagawa K, et al. Clinical relevance of CD70 expression in resected pancreatic cancer: Prognostic value and therapeutic potential. Pancreatology. 2021;21(3):573\u201380.","journal-title":"Pancreatology"},{"issue":"12","key":"1525_CR9","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.7150\/ijbs.42080","volume":"16","author":"Z Chen","year":"2020","unstructured":"Chen Z, Yang X, Bi G, Liang J, Hu Z, Zhao M, et al. Ligand-receptor interaction atlas within and between tumor cells and T cells in lung adenocarcinoma. Int J Biol Sci. 2020;16(12):2205\u201319.","journal-title":"Int J Biol Sci"},{"key":"1525_CR10","doi-asserted-by":"publisher","first-page":"5807","DOI":"10.2147\/IJGM.S325467","volume":"14","author":"K Shen","year":"2021","unstructured":"Shen K, Liu T. Comprehensive analysis of the prognostic value and immune function of immune checkpoints in stomach adenocarcinoma. Int J Gen Med. 2021;14:5807\u201324.","journal-title":"Int J Gen Med"},{"issue":"2","key":"1525_CR11","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1002\/path.5361","volume":"250","author":"S Inaguma","year":"2020","unstructured":"Inaguma S, Lasota J, Czapiewski P, Langfort R, Rys J, Szpor J, et al. CD70 expression correlates with a worse prognosis in malignant pleural mesothelioma patients via immune evasion and enhanced invasiveness. J Pathol. 2020;250(2):205\u201316.","journal-title":"J Pathol"},{"key":"1525_CR12","doi-asserted-by":"publisher","first-page":"615","DOI":"10.2147\/OTT.S44445","volume":"6","author":"N Liu","year":"2013","unstructured":"Liu N, Sheng X, Liu Y, Zhang X, Yu J. Increased CD70 expression is associated with clinical resistance to cisplatin-based chemotherapy and poor survival in advanced ovarian carcinomas. Onco Targets Ther. 2013;6:615\u20139.","journal-title":"Onco Targets Ther"},{"issue":"2","key":"1525_CR13","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41573-018-0004-1","volume":"18","author":"X Chen","year":"2019","unstructured":"Chen X, Song E. Turning foes to friends: targeting cancer-associated fibroblasts. Nat Rev Drug Discovery. 2019;18(2):99\u2013115.","journal-title":"Nat Rev Drug Discovery"},{"issue":"1","key":"1525_CR14","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1152\/physrev.00048.2019","volume":"101","author":"G Biffi","year":"2021","unstructured":"Biffi G, Tuveson DA. Diversity and biology of cancer-associated fibroblasts. Physiol Rev. 2021;101(1):147\u201376.","journal-title":"Physiol Rev"},{"issue":"5","key":"1525_CR15","doi-asserted-by":"publisher","first-page":"987","DOI":"10.3390\/cancers13050987","volume":"13","author":"A Domen","year":"2021","unstructured":"Domen A, Quatannens D, Zanivan S, Deben C, Van Audenaerde J, Smits E, et al. Cancer-associated fibroblasts as a common orchestrator of therapy resistance in lung and pancreatic cancer. Cancers (Basel). 2021;13(5):987.","journal-title":"Cancers (Basel)."},{"issue":"6","key":"1525_CR16","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.ccr.2014.04.005","volume":"25","author":"BC \u00d6zdemir","year":"2014","unstructured":"\u00d6zdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu CC, Simpson TR, et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell. 2014;25(6):719\u201334.","journal-title":"Cancer Cell"},{"issue":"6","key":"1525_CR17","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1084\/jem.20122344","volume":"210","author":"EW Roberts","year":"2013","unstructured":"Roberts EW, Deonarine A, Jones JO, Denton AE, Feig C, Lyons SK, et al. Depletion of stromal cells expressing fibroblast activation protein-\u03b1 from skeletal muscle and bone marrow results in cachexia and anemia. J Exp Med. 2013;210(6):1137\u201351.","journal-title":"J Exp Med"},{"issue":"6","key":"1525_CR18","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1159\/000446569","volume":"83","author":"A De Meulenaere","year":"2016","unstructured":"De Meulenaere A, Vermassen T, Aspeslagh S, Zwaenepoel K, Deron P, Duprez F, et al. CD70 expression and its correlation with clinicopathological variables in squamous cell carcinoma of the head and neck. Pathobiology. 2016;83(6):327\u201333.","journal-title":"Pathobiology"},{"issue":"7","key":"1525_CR19","doi-asserted-by":"publisher","first-page":"e1440167","DOI":"10.1080\/2162402X.2018.1440167","volume":"7","author":"J Jacobs","year":"2018","unstructured":"Jacobs J, Deschoolmeester V, Zwaenepoel K, Flieswasser T, Deben C, Van den Bossche J, et al. Unveiling a CD70-positive subset of cancer-associated fibroblasts marked by pro-migratory activity and thriving regulatory T cell accumulation. Oncoimmunology. 2018;7(7):e1440167.","journal-title":"Oncoimmunology"},{"issue":"4","key":"1525_CR20","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s00428-019-02565-1","volume":"475","author":"S Inoue","year":"2019","unstructured":"Inoue S, Ito H, Tsunoda T, Murakami H, Ebi M, Ogasawara N, et al. CD70 expression in tumor-associated fibroblasts predicts worse survival in colorectal cancer patients. Virchows Arch. 2019;475(4):425\u201334.","journal-title":"Virchows Arch"},{"issue":"7","key":"1525_CR21","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41573-021-00189-2","volume":"20","author":"AJ Hou","year":"2021","unstructured":"Hou AJ, Chen LC, Chen YY. Navigating CAR-T cells through the solid-tumour microenvironment. Nat Rev Drug Discovery. 2021;20(7):531\u201350.","journal-title":"Nat Rev Drug Discovery"},{"issue":"1","key":"1525_CR22","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1158\/2159-8290.CD-20-0556","volume":"11","author":"M Daher","year":"2021","unstructured":"Daher M, Rezvani K. Outlook for new CAR-based therapies with a focus on CAR NK cells: what lies beyond CAR-engineered T cells in the race against cancer. Cancer Discov. 2021;11(1):45\u201358.","journal-title":"Cancer Discov"},{"issue":"1","key":"1525_CR23","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s13045-022-01382-5","volume":"15","author":"N Lamers-Kok","year":"2022","unstructured":"Lamers-Kok N, et al. Natural killer cells in clinical development as non-engineered, engineered, and combination therapies. J Hematol Oncol. 2022;15(1):164.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"1525_CR24","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13045-023-01435-3","volume":"16","author":"R Huang","year":"2023","unstructured":"Huang R, Wen Q, Zhang X. CAR-NK cell therapy for hematological malignancies: recent updates from ASH 2022. J Hematol Oncol. 2023;16(1):35.","journal-title":"J Hematol Oncol"},{"key":"1525_CR25","unstructured":"R Core Team R. R: A language and environment for statistical computing. 2013."},{"issue":"1","key":"1525_CR26","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1186\/s12935-021-02252-9","volume":"21","author":"H Zheng","year":"2021","unstructured":"Zheng H, Liu H, Ge Y, Wang X. Integrated single-cell and bulk RNA sequencing analysis identifies a cancer associated fibroblast-related signature for predicting prognosis and therapeutic responses in colorectal cancer. Cancer Cell Int. 2021;21(1):552.","journal-title":"Cancer Cell Int"},{"issue":"1","key":"1525_CR27","doi-asserted-by":"publisher","first-page":"2192100","DOI":"10.1080\/2162402X.2023.2192100","volume":"12","author":"T Flieswasser","year":"2023","unstructured":"Flieswasser T, Van den Eynde A, Freire Boullosa L, Melis J, Hermans C, Merlin C, et al. Targeting CD70 in combination with chemotherapy to enhance the anti-tumor immune effects in non-small cell lung cancer. Oncoimmunology. 2023;12(1):2192100.","journal-title":"Oncoimmunology"},{"issue":"15","key":"1525_CR28","doi-asserted-by":"publisher","first-page":"13462","DOI":"10.18632\/oncotarget.3880","volume":"6","author":"J Jacobs","year":"2015","unstructured":"Jacobs J, Zwaenepoel K, Rolfo C, Van den Bossche J, Deben C, Silence K, et al. Unlocking the potential of CD70 as a novel immunotherapeutic target for non-small cell lung cancer. Oncotarget. 2015;6(15):13462\u201375.","journal-title":"Oncotarget"},{"issue":"15","key":"1525_CR29","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.2217\/imt-2022-0049","volume":"15","author":"V Siozopoulou","year":"2023","unstructured":"Siozopoulou V, Smits E, Zwaenepoel K, Liu J, Pouliakis A, Pauwels PA, et al. PD-1, PD-L1, IDO, CD70 and microsatellite instability as potential targets to prevent immune evasion in sarcomas. Immunotherapy. 2023;15(15):1257\u201373.","journal-title":"Immunotherapy"},{"key":"1525_CR30","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.biomaterials.2015.03.012","volume":"54","author":"E De Vlieghere","year":"2015","unstructured":"De Vlieghere E, Gremonprez F, Verset L, Mari\u00ebn L, Jones CJ, De Craene B, et al. Tumor-environment biomimetics delay peritoneal metastasis formation by deceiving and redirecting disseminated cancer cells. Biomaterials. 2015;54:148\u201357.","journal-title":"Biomaterials"},{"issue":"10","key":"1525_CR31","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1038\/labinvest.3700329","volume":"85","author":"R Jesnowski","year":"2005","unstructured":"Jesnowski R, F\u00fcrst D, Ringel J, Chen Y, Schr\u00f6del A, Kleeff J, et al. Immortalization of pancreatic stellate cells as an in vitro model of pancreatic fibrosis: deactivation is induced by matrigel and N-acetylcysteine. Lab Invest. 2005;85(10):1276\u201391.","journal-title":"Lab Invest"},{"issue":"6","key":"1525_CR32","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1007\/s10620-015-4001-5","volume":"61","author":"S Hamada","year":"2016","unstructured":"Hamada S, Masamune A, Yoshida N, Takikawa T, Shimosegawa T. IL-6\/STAT3 plays a regulatory role in the interaction between pancreatic stellate cells and cancer cells. Dig Dis Sci. 2016;61(6):1561\u201371.","journal-title":"Dig Dis Sci"},{"issue":"1","key":"1525_CR33","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12967-022-03326-6","volume":"20","author":"G Roex","year":"2022","unstructured":"Roex G, Campillo-Davo D, Flumens D, Shaw PAG, Krekelbergh L, De Reu H, et al. Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells. J Transl Med. 2022;20(1):124.","journal-title":"J Transl Med"},{"issue":"34","key":"1525_CR34","doi-asserted-by":"publisher","first-page":"56968","DOI":"10.18632\/oncotarget.18185","volume":"8","author":"JRM Van Audenaerde","year":"2017","unstructured":"Van Audenaerde JRM, De Waele J, Marcq E, Van Loenhout J, Lion E, Van den Bergh JMJ, et al. Interleukin-15 stimulates natural killer cell-mediated killing of both human pancreatic cancer and stellate cells. Oncotarget. 2017;8(34):56968.","journal-title":"Oncotarget"},{"issue":"5","key":"1525_CR35","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1038\/s41416-020-0934-3","volume":"123","author":"H Baysal","year":"2020","unstructured":"Baysal H, De Pauw I, Zaryouh H, De Waele J, Peeters M, Pauwels P, et al. Cetuximab-induced natural killer cell cytotoxicity in head and neck squamous cell carcinoma cell lines: investigation of the role of cetuximab sensitivity and HPV status. Br J Cancer. 2020;123(5):752\u201361.","journal-title":"Br J Cancer"},{"key":"1525_CR36","first-page":"e64434","volume":"190","author":"M Au-Le Compte","year":"2022","unstructured":"Au-Le Compte M, et al. Multiparametric tumor organoid drug screening using widefield live-cell imaging for bulk and single-organoid analysis. JoVE. 2022;190:e64434.","journal-title":"JoVE"},{"key":"1525_CR37","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s41698-023-00480-y","volume":"7","author":"M Le Compte","year":"2023","unstructured":"Le Compte M, De La Hoz EC, Peeters S, et al. Single-organoid analysis reveals clinically relevant treatment-resistant and invasive subclones in pancreatic cancer. npj Precis Onc. 2023;7:128.","journal-title":"npj Precis Onc"},{"issue":"2","key":"1525_CR38","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s13402-022-00750-0","volume":"46","author":"C Deben","year":"2023","unstructured":"Deben C, De La Hoz EC, Compte ML, Van Schil P, Hendriks JMH, Lauwers P, et al. OrBITS: label-free and time-lapse monitoring of patient derived organoids for advanced drug screening. Cell Oncol (Dordr). 2023;46(2):299\u2013314.","journal-title":"Cell Oncol (Dordr)"},{"issue":"1","key":"1525_CR39","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1186\/s13104-020-05284-y","volume":"13","author":"SA Fisher","year":"2020","unstructured":"Fisher SA, Peddle-McIntyre CJ, Burton K, Newton RU, Marcq E, Lake RA, et al. Voluntary exercise in mesothelioma: effects on tumour growth and treatment response in a murine model. BMC Res Notes. 2020;13(1):435.","journal-title":"BMC Res Notes"},{"issue":"26","key":"1525_CR40","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531\u201344.","journal-title":"N Engl J Med"},{"issue":"5","key":"1525_CR41","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439\u201348.","journal-title":"N Engl J Med"},{"issue":"2","key":"1525_CR42","doi-asserted-by":"publisher","first-page":"194","DOI":"10.3390\/pharmaceutics12020194","volume":"12","author":"G Roex","year":"2020","unstructured":"Roex G, Feys T, Beguin Y, Kerre T, Poir\u00e9 X, Lewalle P, et al. Chimeric antigen receptor-T-cell therapy for B-cell hematological malignancies: an update of the pivotal clinical trial data. Pharmaceutics. 2020;12(2):194.","journal-title":"Pharmaceutics"},{"issue":"5","key":"1525_CR43","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1038\/s41423-021-00655-2","volume":"18","author":"G Liu","year":"2021","unstructured":"Liu G, Rui W, Zhao X, Lin X. Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment. Cell Mol Immunol. 2021;18(5):1085\u201395.","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"1525_CR44","doi-asserted-by":"publisher","first-page":"5110","DOI":"10.1038\/s41467-023-40850-5","volume":"14","author":"Z Xiao","year":"2023","unstructured":"Xiao Z, Todd L, Huang L, Noguera-Ortega E, Lu Z, Huang L, et al. Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors. Nat Commun. 2023;14(1):5110.","journal-title":"Nat Commun"},{"issue":"9","key":"1525_CR45","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1038\/s41591-020-0910-8","volume":"26","author":"C Riether","year":"2020","unstructured":"Riether C, Pabst T, H\u00f6pner S, Bacher U, Hinterbrandner M, Banz Y, et al. Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents. Nat Med. 2020;26(9):1459\u201367.","journal-title":"Nat Med"},{"issue":"16","key":"1525_CR46","doi-asserted-by":"publisher","first-page":"4304","DOI":"10.1182\/blood-2010-04-278218","volume":"117","author":"DR Shaffer","year":"2011","unstructured":"Shaffer DR, Savoldo B, Yi Z, Chow KKH, Kakarla S, Spencer DM, et al. T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies. Blood. 2011;117(16):4304\u201314.","journal-title":"Blood"},{"issue":"9","key":"1525_CR47","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1158\/1078-0432.CCR-16-1421","volume":"23","author":"QJ Wang","year":"2017","unstructured":"Wang QJ, Yu Z, Hanada K-i, Patel K, Kleiner D, Restifo NP, et al. Preclinical evaluation of chimeric antigen receptors targeting CD70-expressing cancers. Clin Cancer Res. 2017;23(9):2267\u201376.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1525_CR48","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1182\/blood.2020008221","volume":"138","author":"T Sauer","year":"2021","unstructured":"Sauer T, Parikh K, Sharma S, Omer B, Sedloev D, Chen Q, et al. CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity. Blood. 2021;138(4):318\u201330.","journal-title":"Blood"},{"issue":"14","key":"1525_CR49","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1158\/0008-5472.CAN-21-2931","volume":"82","author":"SH Panowski","year":"2022","unstructured":"Panowski SH, Srinivasan S, Tan N, Tacheva-Grigorova SK, Smith B, Mak YSL, et al. Preclinical development and evaluation of allogeneic CAR T cells targeting CD70 for the treatment of renal cell carcinoma. Can Res. 2022;82(14):2610\u201324.","journal-title":"Can Res"},{"issue":"2","key":"1525_CR50","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.ccell.2023.01.007","volume":"41","author":"MB Nilsson","year":"2023","unstructured":"Nilsson MB, Yang Y, Heeke S, Patel SA, Poteete A, Udagawa H, et al. CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance. Cancer Cell. 2023;41(2):340-55.e6.","journal-title":"Cancer Cell"},{"key":"1525_CR51","doi-asserted-by":"publisher","DOI":"10.1101\/2023.01.22.523482","author":"M De Stijn","year":"2023","unstructured":"De Stijn M, Juliane B, De Laurenz C, Van Alexander P, Willem D, Eva P, et al. Knocking out CD70 rescues CD70-specific nanoCAR T cells from antigen induced exhaustion. bioRxiv. 2023. https:\/\/doi.org\/10.1101\/2023.01.22.523482.","journal-title":"bioRxiv."},{"key":"1525_CR52","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1007\/s00262-023-03422-6","volume":"72","author":"J Cheng","year":"2023","unstructured":"Cheng J, Ge T, Zhu X, Wang J, Zeng Y, Mu W, et al. Preclinical development and evaluation of nanobody-based CD70-specific CAR T cells for the treatment of acute myeloid leukemia. Cancer Immunol Immunother. 2023;72:2331\u201346.","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"1525_CR53","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41591-021-01621-1","volume":"28","author":"J Mansilla-Soto","year":"2022","unstructured":"Mansilla-Soto J, Eyquem J, Haubner S, Hamieh M, Feucht J, Paillon N, et al. HLA-independent T cell receptors for targeting tumors with low antigen density. Nat Med. 2022;28(2):345\u201352.","journal-title":"Nat Med"},{"issue":"5","key":"1525_CR54","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.ccell.2022.04.001","volume":"40","author":"MB Leick","year":"2022","unstructured":"Leick MB, Silva H, Scarf\u00f2 I, Larson R, Choi BD, Bouffard AA, et al. Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia. Cancer Cell. 2022;40(5):494-508.e5.","journal-title":"Cancer Cell"},{"key":"1525_CR55","doi-asserted-by":"publisher","first-page":"3463","DOI":"10.1182\/blood-2023-190612","volume":"142","author":"P Lin","year":"2023","unstructured":"Lin P, Reyes Silva FC, Lin P, Gilbert AL, Acharya S, Nunez Cortes AK, et al. CD70 CAR NK cells in the treatment of multiple Myeloma. Blood. 2023;142:3463.","journal-title":"Blood"},{"issue":"1","key":"1525_CR56","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s13045-021-01168-1","volume":"14","author":"F Ji","year":"2021","unstructured":"Ji F, Zhang F, Zhang M, Long K, Xia M, Lu F, et al. Targeting the DNA damage response enhances CD70 CAR-T cell therapy for renal carcinoma by activating the cGAS-STING pathway. J Hematol Oncol. 2021;14(1):152.","journal-title":"J Hematol Oncol"},{"issue":"6","key":"1525_CR57","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1158\/2159-8290.CD-18-1218","volume":"9","author":"C Pantelidou","year":"2019","unstructured":"Pantelidou C, Sonzogni O, De Oliveria TM, Mehta AK, Kothari A, Wang D, et al. PARP inhibitor efficacy depends on CD8+ T-cell recruitment via intratumoral STING pathway activation in BRCA-deficient models of triple-negative breast cancer. Cancer Discov. 2019;9(6):722\u201337.","journal-title":"Cancer Discov"},{"issue":"10","key":"1525_CR58","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1007\/s00262-023-03475-7","volume":"72","author":"J Cheng","year":"2023","unstructured":"Cheng J, Zhao Y, Hu H, Tang L, Zeng Y, Deng X, et al. Revealing the impact of CD70 expression on the manufacture and functions of CAR-70T-cells based on single-cell transcriptomics. Cancer Immunol Immunother. 2023;72(10):3163\u201374.","journal-title":"Cancer Immunol Immunother"},{"issue":"10","key":"1525_CR59","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-022-02003-x","volume":"28","author":"Y Li","year":"2022","unstructured":"Li Y, Basar R, Wang G, Liu E, Moyes JS, Li L, et al. KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape. Nat Med. 2022;28(10):2133\u201344.","journal-title":"Nat Med"},{"issue":"1","key":"1525_CR60","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41416-018-0325-1","volume":"120","author":"N Tokarew","year":"2019","unstructured":"Tokarew N, Ogonek J, Endres S, von Bergwelt-Baildon M, Kobold S. Teaching an old dog new tricks: next-generation CAR T cells. Br J Cancer. 2019;120(1):26\u201337.","journal-title":"Br J Cancer"},{"issue":"2","key":"1525_CR61","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/leu.2017.226","volume":"32","author":"E Liu","year":"2018","unstructured":"Liu E, Tong Y, Dotti G, Shaim H, Savoldo B, Mukherjee M, et al. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. Leukemia. 2018;32(2):520\u201331.","journal-title":"Leukemia"},{"issue":"5","key":"1525_CR62","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1182\/blood.2020007748","volume":"137","author":"M Daher","year":"2021","unstructured":"Daher M, Basar R, Gokdemir E, Baran N, Uprety N, Nunez Cortes AK, et al. Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells. Blood. 2021;137(5):624\u201336.","journal-title":"Blood"},{"issue":"30","key":"1525_CR63","doi-asserted-by":"publisher","first-page":"eadd6997","DOI":"10.1126\/sciadv.add6997","volume":"9","author":"L Li","year":"2023","unstructured":"Li L, Mohanty V, Dou J, Huang Y, Banerjee PP, Miao Q, et al. Loss of metabolic fitness drives tumor resistance after CAR-NK cell therapy and can be overcome by cytokine engineering. Sci Adv. 2023;9(30):eadd6997.","journal-title":"Sci Adv"},{"issue":"12","key":"1525_CR64","doi-asserted-by":"publisher","first-page":"e003894","DOI":"10.1136\/jitc-2021-003894","volume":"9","author":"I Christodoulou","year":"2021","unstructured":"Christodoulou I, Ho WJ, Marple A, Ravich JW, Tam A, Rahnama R, et al. Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities. J Immunother Cancer. 2021;9(12):e003894.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"1525_CR65","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1186\/s12967-022-03626-x","volume":"20","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Zhuang Q, Wang F, Zhang C, Xu C, Gu A, et al. Co-expression IL-15 receptor alpha with IL-15 reduces toxicity via limiting IL-15 systemic exposure during CAR-T immunotherapy. J Transl Med. 2022;20(1):432.","journal-title":"J Transl Med"},{"issue":"298","key":"1525_CR66","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1126\/scitranslmed.aab1740","volume":"7","author":"C Riether","year":"2015","unstructured":"Riether C, Sch\u00fcrch CM, Flury C, Hinterbrandner M, Dr\u00fcck L, Huguenin AL, et al. Tyrosine kinase inhibitor-induced CD70 expression mediates drug resistance in leukemia stem cells by activating Wnt signaling. Sci Transl Med. 2015;7(298):298\u2013119.","journal-title":"Sci Transl Med."},{"issue":"7","key":"1525_CR67","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.3324\/haematol.2022.281563","volume":"108","author":"T Pabst","year":"2023","unstructured":"Pabst T, Vey N, Ad\u00e8s L, Bacher U, Bargetzi M, Fung S, et al. Results from a phase I\/II trial of cusatuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy. Haematologica. 2023;108(7):1793\u2013802.","journal-title":"Haematologica"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-024-01525-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-024-01525-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-024-01525-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T01:43:19Z","timestamp":1707442999000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-024-01525-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,9]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1525"],"URL":"https:\/\/doi.org\/10.1186\/s13045-024-01525-w","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,9]]},"assertion":[{"value":"22 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The usage of PDAC patient tissue blocks from the Antwerp Biobank (Antwerp, Belgium; ID: BE71030031000) was approved by the Ethics Committee of the Antwerp University Hospital-University of Antwerp under study reference EC14\/47\/480 and EC13\/47\/469. The generation of patient-derived organoids from PDAC patients was carried out after written consent and approved by the Ethics Committee of the Antwerp University Hospital-University of Antwerp under study reference EC14\/47\/480. Buffy coats from four healthy donors were provided by the Red Cross Flanders and usage was approved by the UZA-UAntwerp Ethics Committee under study reference EC5488. All animal procedures were conducted in accordance with, and approval of, the Animal Ethics Committee of the UAntwerp under registration number 2021-55.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8"}}